Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 5, 1995, Pages 678-682

  Nawrocki, James W ^a   Weiss, Stuart R ^b   Davidson, Michael H ^c   Sprecher, Dennis L ^d   Schwartz, Sherwyn L ^e   Lupien, Paul J ^f   Jones, Peter H ^g   Haber, Harry E ^a   Black, Donald M ^a  

^a PFIZER INC   (United States)

^b S Diego Endocr and Medical Clinic   (United States)

^c RADIANT RESEARCH   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e Diabetes and Glandular Disease Clinic   (United States)

^f Lipid Research Center   (Canada)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

atorvastatin; coronary disease; hydroxymethylglutaryl CoA reductase; hypercholesterolemia; LDL cholesterol

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INDIGESTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029043903     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.15.5.678     Document Type: Article

References (25)

1. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 1988:148:36-69.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
3. European Atherosclerosis Society. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis. 1992;2:113-156.
4. Illingworth DR. New horizons in combination drug therapy for hypercholesterolemia. Cardiology. 1989;76(suppl 1):83-100.
5. Hunninghake DB. HMG CoA reductase inhibitors. Curr Opin Lipidol. 1992;3:22-28.
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
7. Merck & Co, Inc. Mevacor prescribing information. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Data, a division of Medical Economics Company Inc; 1993:1556-1560.
8. ER Squibb & Sons, Inc, a Bristol-Myers Squibb Co. Pravachol prescribing information. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Data, a division of Medical Economics Company Inc; 1993:2362-2365.
9. Merck & Co, Inc. Zocor prescribing information. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Data, a division of Medical Economics Company Inc; 1993:1625-1628.
10. Baumann KL, Butler DE, Deering CF, Mennen KE, Millar A, Nanninga TN, Palmer CW, Roth BD. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 1992;33:2283-2284.
11. Krause BR, Bousley R, Kieft K, Stanfield R, Newton RS. CI-981 is superior to lovastatin for lowering plasma triglycerides in experimental animals. FASEB J. 1993;7:A567. Abstract.
12. McGuire E, Bailey D, Dominick M, Morse C, Sigler R, Walsh K, Susick R. Subchronic evaluation of a liver selective HMG-CoA reductase inhibitor in rodents and dogs. Toxicologist. 1991;11:151. Abstract.
13. Cilla DD Jr, Posvar EL, Sedman AJ. Multiple-dose tolerance and pharmacologic effect of CI-981. J Clin Pharmacol 1992;32:749. Abstract.
14. Remmell PS, Gorder DD, Hall Y, Tiilotson JL. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT), 1: use of a dietary monitoring tool. J Am Diet Assoc. 1980;76: 3351-3356.
15. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control - National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135.
16. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics' methodology. J Clin Chem Clin Biochem. 1981;19:850. Abstract.
17. Steele WB, Koehle DF, Azar MM, Blaszkowski TP, Kuba K, Dempsey ME. Enzymatic determinations of cholesterol in high density lipoprotein fractions prepared by a precipitation technique. Clin Chem. 1976;22:98-101.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the ultracentrifuge. Clin Chem. 1972;18:449-502.
19. Lipid and lipoprotein analysis. In: Manual of Laboratory Operations: Lipid Research Clinics Program Report. Washington, DC: 1974. US Department of Health, Education and Welfare publication NIH 75-628, vol 1.
20. Marcovina SM, Adolphson JL, Parlavecchia M, Albers JJ. Effects of lyophilization of serum on the measurement of apolipoproteins A-I and B. Clin Chem. 1990;36:366-369.
21. Marcovina SM, Albers JJ, Henderson LO, Hannon HW. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. III: comparability of apolipoprotein A-I values by use of international reference material. Clin Chem. 1993;39:773-781.
22. Stein E, Kumbla L, Miller J, Srivastiva L, Kashyap M. Development and evaluation of a competitive ELISA for Lp(a). Clin Chem. 1992;38:1067. Abstract.
23. SAS/STAT User's Guide, Version 6, 4th ed. Cary, NC: SAS Institute Inc; 1989.
24. Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA. 1988;260:359-366.
25. Prihoda JS, Illingworth DR. Drug therapy of hyperlipidemia. Curr Probl Cardiol. 1992;17:547-605.